RxDoctor Payments Data

Sara Cerrone, MD

Gastroenterology · Riverhead, NYNPI 1043585276

Payments from drug & device makers

$1,558in general payments, 2019–2025

Across 12 payments — averaging $129.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$422
  • Covidien LP$407
  • Ironwood Pharmaceuticals, Inc$125
  • Boehringer Ingelheim$125
  • Dova Pharmaceuticals$124
  • GSK$117
  • plus $239 from 3 others

What the payments were for

  • Travel & lodging$30319%
  • Food & beverage$1,25681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,558 in reported general payments places this provider in the 45th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$210,815
Medicare patients
562
Services billed
1,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin36$157,695
LinzessLinaclotide43$57,720
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates106$6,264
Sucralfate24$3,263
SutabSod Sulf/Pot Chloride/Mag Sulf20$3,193
Omeprazole186$3,100
Pantoprazole Sodium182$2,527
Famotidine136$1,971
Balsalazide Disodium13$1,870
Mesalamine ErMesalamine12$1,124
Esomeprazole Magnesium15$984
Dicyclomine Hcl21$835
Ondansetron Hcl27$165
Carvedilol12$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$33$57,72043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Riverhead

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →